[1]     Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis[J]. J Gen Intern Med, 2004,19(7):791-804.



[2]     Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy post- menopausal women[J]. JAMA, 2002, 288: 321-333.



[3]     Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study[J]. Breast Cancer Res Treat, 2008, 107(1):103-111.



[4]     Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised trial[J]. Lancet Oncol, 2012, 13: 476-486.



[5]     Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial[J]. BMJ, 2012, 345: e6409.



[6]     Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy[J]. Maturitas, 2013, 74(4): 391-392.



[7]     Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health[J]. Climacteric, 2013, 16: 316-337.



[8]     North American Menopause Society.The 2012 hormone therapy position statement of the North American Menopause Society[J]. Menopause, 2012, 19(3): 257-271.



[9]     Panay N, Hamoda H, Arya R, et al. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy[J]. Menopause Int, 2013, 19(2): 59-68.



[10]     中华医学会妇产科学分会绝经学组. 绝经期管理与激素补充治疗临床应用指南[J]. 中华妇产科杂志, 2013, 48（10）：795-799.



（2015-10-12 收稿）